{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:41:36Z","timestamp":1790664096810,"version":"4.1.0"},"reference-count":47,"publisher":"Japanese Circulation Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2019,7,10]]},"DOI":"10.1253\/circrep.cr-19-0018","type":"journal-article","created":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T22:04:26Z","timestamp":1562105066000},"page":"286-295","source":"Crossref","is-referenced-by-count":43,"title":["Effects of Sodium-Glucose Cotransporter 2 Inhibitor on Vascular Endothelial and Diastolic Function in Heart Failure With Preserved Ejection Fraction\u3000\u2015 Novel Prospective Cohort Study \u2015"],"prefix":"10.1253","volume":"1","author":[{"given":"Takaaki","family":"Sakai","sequence":"first","affiliation":[{"name":"Department of Cardiology, Ichijyukai NISHIO Hospital"},{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Miura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fukuoka University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. <i>N Engl J Med<\/i> 2006; 355: 251\u2013259.","DOI":"10.1056\/NEJMoa052256"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT, et al. Systolic and diastolic heart failure in the community. <i>JAMA<\/i> 2006; 296: 2209\u20132216.","DOI":"10.1001\/jama.296.18.2209"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gurwitz JH, Magid DJ, Smith DH, Goldberg RJ, McManus DD, Allen LA, et al. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. <i>Am J Med<\/i> 2013; 126: 393\u2013400.","DOI":"10.1016\/j.amjmed.2012.10.022"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Berry C, Hogg K, Norrie J, Stevenson K, Brett M, McMurray J. Heart failure with preserved left ventricular systolic function: A hospital cohort study. <i>Heart<\/i> 2005; 91: 907\u2013913.","DOI":"10.1136\/hrt.2004.041996"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. <i>N Engl J Med<\/i> 2006; 355: 260\u2013269.","DOI":"10.1056\/NEJMoa051530"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O\u2019Connor CM, She L, et al; OPTMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. <i>JAMA<\/i> 2006; 296: 2217\u20132226.","DOI":"10.1001\/jama.296.18.2217"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al; Get With the Guidelines Scientific Advisory Committee and Investigators. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: Prevalence, therapies, and outcomes. <i>Circulation<\/i> 2012; 126: 65\u201375.","DOI":"10.1161\/CIRCULATIONAHA.111.080770"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. <i>N Engl J Med<\/i> 2015; 373: 2117\u20132128.","DOI":"10.1056\/NEJMoa1504720"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. <i>N Engl J Med<\/i> 2016; 375: 23\u201334.","DOI":"10.1056\/NEJMoa1515920"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, et al; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study). <i>Circulation<\/i> 2018; 137: 323\u2013334.","DOI":"10.1161\/CIRCULATIONAHA.117.032038"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. <i>N Engl J Med<\/i> 2017; 377: 644\u2013657.","DOI":"10.1056\/NEJMoa1611925"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lundbaek K. Diabetic angiopathy: A specific vascular disease. <i>Lancet<\/i> 1954; 266: 377\u2013379.","DOI":"10.1016\/S0140-6736(54)90924-1"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. <i>Am J Cardiol<\/i> 1972; 30: 595\u2013602.","DOI":"10.1016\/0002-9149(72)90595-4"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>Eur Heart J<\/i> 2008; 29: 270\u2013276.","DOI":"10.1093\/eurheartj\/ehm342"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Forbes JM, Cooper ME. Mechanisms of diabetic complications. <i>Physiol Rev<\/i> 2013; 93: 137\u2013188.","DOI":"10.1152\/physrev.00045.2011"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>J Am Soc Echocardiogr<\/i> 2016; 29: 277\u2013314.","DOI":"10.1016\/j.echo.2016.01.011"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Oeing CU, Tsch\u00f6pe C, Pieske B. The new ESC Guidelines for acute and chronic heart failure 2016. <i>Herz<\/i> 2016; 41: 655\u2013663.","DOI":"10.1007\/s00059-016-4496-3"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community. <i>JAMA<\/i> 2003; 289: 194\u2013202.","DOI":"10.1001\/jama.289.2.194"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Abhayaratna WP. Characteristics of left ventricular diastolic dysfunction in the community: An echocardiographic survey. <i>Heart<\/i> 2006; 92: 1259\u20131264.","DOI":"10.1136\/hrt.2005.080150"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. <i>J Am Coll Cardiol<\/i> 2002; 39: 257\u2013265.","DOI":"10.1016\/S0735-1097(01)01746-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Shigiyama F, Kumashiro N, Miyagi M, Iga R, Kobayashi Y, Kanda E, et al. Linagliptin improves endothelial function in patients with type 2 diabetes: A randomized study of linagliptin effectiveness on endothelial function. <i>J Diabetes Investig<\/i> 2017; 8: 330\u2013340.","DOI":"10.1111\/jdi.12587"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. <i>Eur J Pharmacol<\/i> 2013; 715: 246\u2013255.","DOI":"10.1016\/j.ejphar.2013.05.014"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Oelze M, Kr\u00f6ller-Sch\u00f6n S, Welschof P, Jansen T, Hausding M, Mikhed Y, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. <i>PLoS One<\/i> 2014; 9: e112394.","DOI":"10.1371\/journal.pone.0112394"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Wu JH, Foote C, Blomster J, Toyama T, Perkovic V, Sundstr\u00f6m J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis. <i>Lancet Diabetes Endocrinol<\/i> 2016; 4: 411\u2013419.","DOI":"10.1016\/S2213-8587(16)00052-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, et al. Diastolic stiffness of the failing diabetic heart: Importance of fibrosis, advanced glycation end products, and myocyte resting tension. <i>Circulation<\/i> 2008; 117: 43\u201351.","DOI":"10.1161\/CIRCULATIONAHA.107.728550"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. <i>Circ Res<\/i> 2001; 88: e14\u2013e22.","DOI":"10.1161\/01.RES.88.2.e14"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Schuhmacher S, Oelze M, Bollmann F, Kleinert H, Otto C, Heeren T, et al. Vascular dysfunction in experimental diabetes is improved by pentaerithrityl tetranitrate but not isosorbide-5-mononitrate therapy. <i>Diabetes<\/i> 2011; 60: 2608\u20132616.","DOI":"10.2337\/db10-1395"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Oelze M, Knorr M, Schuhmacher S, Heeren T, Otto C, Schulz E, et al. Vascular dysfunction in streptozocin-induced experimental diabetes strictly depends on insulin deficiency. <i>J Vasc Res<\/i> 2011; 48: 275\u2013284.","DOI":"10.1159\/000320627"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. <i>Cardiovasc Res<\/i> 2004; 63: 582\u2013592.","DOI":"10.1016\/j.cardiores.2004.05.001"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Calcutt NA, Cooper ME, Kern TS, Schmidt AM. Therapies for hyperglycaemia-induced diabetic complications: From animal models to clinical trials. <i>Nat Rev Drug Discov<\/i> 2009; 8: 417\u2013430.","DOI":"10.1038\/nrd2476"},{"key":"31","unstructured":"31. Sun M, Yokohama M, Ishiwata T, Asano G. Deposition of advanced glycation end products (AGE) and expression of the receptor for AGE in cardiovascular tissue of the diabetic rat. <i>Int J Exp Pathol<\/i> 1998; 79: 207\u2013222."},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Omori K, Kotera J. Overview of PDEs and their regulation. <i>Circ Res<\/i> 2007; 100: 309\u201327.","DOI":"10.1161\/01.RES.0000256354.95791.f1"},{"key":"33","unstructured":"33. Lee DI, Kass DA. Phosphodiesterases and cyclic GMP regulation in heart muscle. <i>Physiology (Bethesda)<\/i> 2012; 27: 248\u2013258."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kirk JA, Holewinski RJ, Crowgey EL, Van Eyk JE. Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials. <i>Proteomics<\/i> 2016; 16: 894\u2013905.","DOI":"10.1002\/pmic.201500401"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Ter Maaten JM, Damman K, Verhaar MC, Paulus WJ, Duncker DJ, Cheng C, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: The role of endothelial dysfunction and inflammation. <i>Eur J Heart Fail<\/i> 2016; 18: 588\u2013598.","DOI":"10.1002\/ejhf.497"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Klein DA, Katz DH, Beussink-Nelson L, Sanchez CL, Strzelczyk TA, Shah SJ. Association of chronic kidney disease with chronotropic incompetence in heart failure with preserved ejection fraction. <i>Am J Cardiol<\/i> 2015; 116: 1093\u20131100.","DOI":"10.1016\/j.amjcard.2015.06.038"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Damkj\u00e6r M, Vafaee M, M\u00f8ller ML, Braad PE, Petersen H, H\u00f8ilund-Carlsen PF, et al. Renal cortical and medullary blood flow responses to altered NO availability in humans. <i>Am J Physiol Regul Integr Comp Physiol<\/i> 2010; 299: R1449\u2013R1455.","DOI":"10.1152\/ajpregu.00440.2010"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Cowley AW Jr, Abe M, Mori T, O\u2019Connor PM, Ohsaki Y, Zheleznova NN. Reactive oxygen species as important determinants of medullary flow, sodium excretion, and hypertension. <i>Am J Physiol Renal Physiol<\/i> 2015; 308: F179\u2013F197.","DOI":"10.1152\/ajprenal.00455.2014"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, et al; EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomized, double-blind, placebo-controlled trial. <i>Lancet Diabetes Endocrinol<\/i> 2014; 2: 369\u2013384.","DOI":"10.1016\/S2213-8587(13)70208-0"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. <i>Diabetes Obes Metab<\/i> 2013; 15: 463\u2013473.","DOI":"10.1111\/dom.12090"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. <i>Kidney Int<\/i> 2014; 85: 962\u2013971.","DOI":"10.1038\/ki.2013.356"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskannenn L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. <i>Lancet<\/i> 2013; 382: 941\u2013950.","DOI":"10.1016\/S0140-6736(13)60683-2"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: A \u201cthrifty substrate\u201d hypothesis. <i>Diabetes Care<\/i> 2016; 39: 1108\u20131114.","DOI":"10.2337\/dc16-0330"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Sano M. Hemodynamic effects of sodium-glucose cotransporter 2 inhibitors. <i>J Clin Med Res<\/i> 2017; 9: 457\u2013460.","DOI":"10.14740\/jocmr3011w"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. <i>Postgrad Med<\/i> 2013; 125: 181\u2013189.","DOI":"10.3810\/pgm.2013.05.2667"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Hach T, Gerich J, Salsai A, Kim G, Hantel S, Woerle H, et al. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): Pooled data from four pivotal phase III trials. <i>Diabetol Stoffw<\/i> 2014; 9: 142 (in German).","DOI":"10.1055\/s-0034-1374999"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Briand F, Mayoux E, Brousseau E, Burr N, Urbain I, Costard C, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. <i>Diabetes<\/i> 2016; 65: 2032\u20132038.","DOI":"10.2337\/db16-0049"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/1\/7\/1_CR-19-0018\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T03:42:02Z","timestamp":1562989322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/1\/7\/1_CR-19-0018\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-19-0018","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]}}}